Rigin 200mg (Palmitoyl Tetrapeptide 7) (Topical)

Peptide Sciences

Topical Research Peptide

Cosmetic anti-ageing lipopeptide (Palmitoyl Tetrapeptide-7)

Supplied as a research Use Only (RUO) peptide and not approved by the FDA, EMA, MHRA or other regulatory agencies as a drug, cosmetic ingredient for commercial sale, or medical device.
Manufactured and tested according to the supplier’s internal quality standards (e.g., ≥99% purity by HPLC) appropriate for research chemicals.

Supplied as a research Use Only (RUO) peptide and not approved by the FDA, EMA, MHRA or other regulatory agencies as a drug, cosmetic ingredient for commercial sale, or medical device.
Manufactured and tested according to the supplier’s internal quality standards (e.g., ≥99% purity by HPLC) appropriate for research chemicals.

Cosmetic anti-ageing lipopeptide (Palmitoyl Tetrapeptide-7)

Description

Rigin 200mg (Palmitoyl Tetrapeptide-7) (Topical) is a high-purity, research-grade cosmetic peptide supplied as a lyophilised powder for topical formulation and in-vitro studies. Rigin is the trade name commonly used for palmitoyl tetrapeptide-7, a lipopeptide with the sequence Pal-Gly-Gln-Pro-Arg (Pal-GQPR), originally developed to mimic part of the immunoglobulin G (IgG) molecule. In experimental models, palmitoyl tetrapeptide-7 has been investigated for its ability to modulate cytokine activity (especially interleukin-6), reduce inflammation, support extracellular matrix homeostasis and stimulate collagen and elastin synthesis in the skin. These properties make it of interest in anti-ageing and skin-repair research, where it may help improve firmness, elasticity, hydration and overall skin texture when incorporated into topical test formulations. This product contains 200 mg of palmitoyl tetrapeptide-7 at ≥99% purity (HPLC) and is labelled for research use only, not for human or veterinary use.

Bnefits

Provides a defined, high-purity source of palmitoyl tetrapeptide-7 (Rigin) for cosmetic and dermatological research.
Investigated for stimulating collagen and elastin synthesis, supporting improved skin firmness and elasticity in experimental systems.
May help reduce the appearance of fine lines and wrinkles and improve overall skin smoothness in topical formulation studies.
Shown in research models to modulate cytokine activity (e.g., IL-6), potentially reducing inflammation-related damage to the extracellular matrix.
Associated with improved skin hydration, barrier support and smoother texture when formulated appropriately in test products.
Lipid (palmitoyl) modification enhances peptide affinity for skin and potential penetration in topical research formulations.
Supplied as a lyophilised powder at ≥99% HPLC purity for reproducible formulation and in-vitro work.
Research-use-only labelling supports safe, controlled use in non-clinical environments.

Indications

In-vitro and ex-vivo research on skin ageing, inflammation and extracellular matrix regulation.
Development and testing of experimental topical cosmetic formulations targeting wrinkles, firmness and elasticity.
Studies on modulation of cytokines (particularly IL-6) and matrix metalloproteinases (MMPs) in skin models.
Combination studies with other cosmetic peptides (e.g., palmitoyl tripeptide-1, Matrixyl 3000 components) to explore synergistic anti-ageing effects.
Not indicated or approved for direct therapeutic use in humans or animals.

Composition

Active ingredient: Palmitoyl Tetrapeptide-7 (Rigin), sequence Pal-Gly-Gln-Pro-Arg (Pal-GQPR).
Molecular formula: C34H62N8O7.
CAS number: 221227-05-0.
Molecular weight: approximately 694.9 g/mol (palmitoylated peptide).
Purity: ≥99% (HPLC), research grade.
Supplied as lyophilised peptide powder without added excipients (carrier-free), unless otherwise specified on the vial label.

Formulation

Physical form: White to off-white lyophilised powder.
Chemical class: Lipo-tetrapeptide (palmitoylated peptide) derived from an IgG fragment.
INCI/trade names commonly associated: Palmitoyl Tetrapeptide-7, Rigin™, N-Palmitoylrigin, Pal-GQPR.
Intended route in research: Topical (for incorporation into experimental creams, serums or gels) and in-vitro test systems.
Typical reconstitution in research: Dissolved in sterile water, buffer or suitable cosmetic solvent phase prior to dilution into final test vehicles (exact conditions determined by the researcher).

Packaging

Standard presentation: 1 x 200 mg vial of lyophilised palmitoyl tetrapeptide-7 powder.
Vial type: Sealed laboratory vial suitable for peptide storage (material and closure specification per supplier).
Primary container labelled with product name (Rigin – Palmitoyl Tetrapeptide-7), amount (200 mg), purity (99% HPLC), CAS number, molecular formula and research-use-only warnings.
Outer packaging: Protective shipping materials to maintain temperature and protect the vial during transit.

Usage

For laboratory research and in-vitro use only; not for human or veterinary use and not for use in finished consumer products without appropriate regulatory clearance.
Allow the vial to reach room temperature before opening to minimise condensation.
Reconstitute the lyophilised powder using a suitable sterile solvent (e.g., sterile water, buffer or relevant cosmetic phase) according to the requirements of the specific study or formulation; mix gently until fully dissolved.
Prepare working dilutions immediately prior to use to minimise peptide degradation; avoid vigorous shaking or foaming.
When formulating into experimental topical vehicles, ensure compatibility with other ingredients (pH, solvent system, preservatives) and protect from excessive heat and light.
Use appropriate aseptic technique and personal protective equipment (PPE) when handling the peptide and any solutions.
Do not inject, ingest or apply directly to humans or animals; all work should comply with institutional safety and ethical guidelines.
Dispose of any unused solutions and materials following local regulations for chemical and biological laboratory waste.

Contraindications

Not for human or veterinary use; must not be injected, ingested, or applied directly to living subjects.
Use is contraindicated outside controlled research settings (e.g., home or cosmetic self-use is not permitted).
Do not use if vial, seal or label is damaged, missing or shows signs of tampering.
Researchers with known hypersensitivity to peptide powders or laboratory chemicals should use caution and appropriate PPE.
Not to be combined with other substances in ways that contravene local safety, chemical or biosafety regulations.

Adverse Effects

No clinical adverse-effect profile is established, as the product is not intended or approved for clinical use.
Laboratory handling risks include potential irritation from dust or aerosols if mishandled; avoid inhalation, ingestion or contact with skin and eyes.
Spills or splashes may cause transient irritation and should be managed with standard laboratory first-aid and decontamination procedures.
Improper storage or handling may lead to peptide degradation, loss of activity or formation of breakdown products, which could affect experimental results.

Storage Conditions

Store lyophilised peptide at approximately −20 °C in a dry, dark environment.
Keep vial tightly closed and protected from moisture, heat and direct light.
Allow vial to reach room temperature before opening to reduce condensation risk.
After reconstitution, store solutions at 2–8 °C for short-term use or aliquot and freeze at −20 °C or below for longer-term storage, as compatible with the specific solvent system.
Avoid repeated freeze–thaw cycles by preparing single-use aliquots where possible.
Always follow any additional storage information provided on the product label or certificate of analysis.

Duration

Not applicable as a finished treatment; duration of exposure or application is defined by the specific research protocol or in-vitro assay design.

Onset

In experimental models, changes in cytokine expression, extracellular matrix markers or skin-related endpoints are typically assessed over hours to weeks, depending on the assay and formulation; no clinically defined onset of effect exists for this research-only product.